Catalyst
Slingshot members are tracking this event:
Phase 2 48-week top-line data of Summit's(SMMT) Ezutromid in treating Duchenne muscular dystrophy due 3Q 2018 - Discontinued
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SMMT | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 29, 2018
Occurred Source:
https://musculardystrophynews.com/2018/06/29/summit-therapeutics-ends-ezutromid-development-trail-failure/
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Duchenne Muscular Dystrophy, Ezutromid, Discontinued, Discontinuation
